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I
n 1961, elegant experiments by Christian Anfinsen first 
demonstrated that a protein, the enzyme ribonuclease 
A, could be reversibly denatured (unfolded) and 
subsequently renatured (refolded) to its functional native 
state [1]. This and subsequent similar findings for many other 
proteins gave rise to a central tenet of protein folding, that 
the information specifying how a protein attains its native 
state is encoded in its primary amino acid sequence. Thus 
was posed “The Protein Folding Problem,” which remains 
a central unsolved problem in biology: exactly how does 
a protein’s primary sequence determine its structure and 
function, or its misfolding and misfunction? 
Until the late 1980s, protein folding was studied by 
relatively few scientists, and the problem was generally 
regarded as fundamental, but of minimal immediate, 
practical importance. With the advent of massive genome 
sequencing efforts and the concomitant recognition that 
many diseases are caused by single amino acid substitutions in 
many different proteins, the drive to understand how primary 
sequence governs folding and function greatly intensified. A 
common feature of numerous mutation-linked diseases is the 
deposition of misfolded protein aggregates. Extensive studies 
have shown that protein aggregates are often misfunctional, 
i.e., toxic to cells, but the nature and targets of the toxic 
aggregated species are not well understood and are still under 
intense investigation. Anfinsen’s and related experiments 
also established that the folding of an unfolded protein 
is not trivial, depending strongly on solution conditions, 
and protein misfolding and aggregation reactions typically 
compete with folding reactions. Furthermore, the difference 
in energy between the native folded state and the unfolded 
state of a protein, which defines its thermodynamic stability, 
is typically small (20–40 kJ mol−1), corresponding to the 
energy of one to several noncovalent interactions (such as 
a hydrogen bond, or salt bridge) among the myriad of such 
interactions occurring in both the folded and unfolded states 
[2]. As a consequence, it is quite easy to significantly alter the 
relative proportions of protein occupying the folded versus 
fully or partially unfolded states, for example by substitution 
of a single amino acid, or by a covalent modification such 
as proteolysis (as is also frequently observed for proteins 
associated with misfolding diseases). 
Thus, it appears that many proteins have evolved to be only 
as stable as they need to be in order to remain largely folded 
and active, but also sufficiently unstable to be easily turned 
over or regulated. Some proteins are not even folded into a 
defined globular shape, and instead populate a fluctuating, 
natively unfolded state that can switch to a folded state 
upon binding of a suitable partner molecule. Such natively 
unfolded proteins have different characteristics from native 
globular proteins, such as a higher proportion of charged 
amino acids and lower proportion of hydrophobic amino 
acids, which decrease their tendency to aggregate [3].  
Molecular Details and Consequences of Protein 
Aggregation
The molecular details of protein aggregation are in 
general not well understood, owing to the complexity and 
variability of misfolding reactions and technical difficulties in 
characterizing aggregates, due to their often heterogeneous 
and fibrillar nature. Aggregate structures can range from 
poorly ordered (amorphous) to highly ordered, and the 
same protein can adopt a range of structures, depending 
on solution conditions. Both amorphous and ordered 
aggregates are often enriched in beta-sheet secondary 
structure. A common type of beta-sheet-based, ordered 
aggregate structure that has been studied extensively is 
known as amyloid [4]. It has been proposed that the ability 
to form amyloid structure is an inherent or generic property 
of polypeptide chains, although the propensity to do so can 
vary dramatically with primary sequence. Amyloid formation 
is associated with a host of diseases—notably prevalent 
neurodegenerative diseases, including Alzheimer, Parkinson, 
and Huntington diseases as well as prion diseases, but also 
non-neuropathic systemic and localized diseases. Amyloid 
aggregates consist of long unbranched fibers of a given 
protein, which forms a “cross-beta” structure in which beta-
strands are oriented perpendicular to the axis of the fiber. 
Also, they exhibit “apple-green” birefringence upon staining 
with Congo red, a dye long used by pathologists to diagnose 
misfolding diseases. The amyloidogenic proteins in the 
different diseases are highly diverse in terms of their primary 
sequences, native structures, and functions, and include both 
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folded globular and natively unfolded proteins. Aggregate 
structures associated with other diseases do not fit all the 
criteria for amyloid, but are often also fibrillar [4,5].
In this issue of PLoS Biology, Wang et al. [6] investigate 
the basis for the formation of nonamyloid, fibrillar 
aggregates by Cu/Zn-superoxide dismutase (SOD1) in 
another neurodegenerative disease: amyotrophic lateral 
sclerosis (ALS), also known as Lou Gehrig disease. ALS is an 
invariably fatal, rapidly progressive motor neuron disease for 
which there is no cure and very little in the way of effective 
treatment. In general, treatments for neurodegenerative 
diseases are very limited, which imparts great urgency to 
research aimed at understanding and combating these 
devastating and widespread diseases.
Principles and Prediction of Protein Aggregation and 
Relation to Disease
What common principles may underlie the aggregation 
of so many different proteins in many different diseases? 
Aggregation is thought usually to occur from partially to 
fully unfolded states of proteins. It is well established that 
destabilization of the native state plays an important role 
in the pathogenic effects of mutations of various globular 
proteins [7]. Examples include mutations of lysozyme 
[8,9], transthyretin [10], and immunoglobulin light chains 
[11,12] in various amyloidoses, and serpins that form 
various nonamyloid aggregates in serpinopathies [5]. 
Seminal research by Dobson and colleagues established an 
equation (referred to here as the Chiti-Dobson equation) for 
predicting the aggregation propensity of unfolded proteins 
based on their biophysical properties [13]. This equation 
has been applied extensively to amyloid formation by mutant 
proteins or peptides associated with disease or toxicity. In the 
Chiti-Dobson equation, the calculated aggregation propensity 
of a protein is increased when mutations decrease net charge, 
increase hydrophobicity, increase beta-sheet propensity, or 
decrease alpha-helix propensity. 
Wang et al. have advanced research on protein folding 
and aggregation by building on existing knowledge in two 
important ways: (1) applying the Chiti-Dobson equation 
to calculate aggregation propensity for mutant forms of 
SOD1 associated with ALS, a nonamyloid disease; and (2) 
combining calculated aggregation propensity quantitatively 
with measured experimental stability of mutant SOD1 to 
define a strong correlation with ALS disease severity as 
measured by patient survival time (i.e., disease duration) [6]. 
In contrast with some other diseases, however, no trends were 
identified between the nature of SOD1 mutations and age of 
disease onset. SOD1 is a homodimeric metalloenzyme, with 
each subunit consisting of a 153 amino acid chain that binds 
a structural zinc ion and a catalytic copper ion. Over 110, 
predominantly missense, mutations located throughout the 
SOD1 structure have been linked to familial forms of ALS 
(http://alsod.iop.kcl.ac.uk/ALS/index.aspx). It has been 
proposed previously that decreased stability of unmetallated 
(apo) SOD1 is correlated with decreased disease duration 
[14], and that disease-associated SOD1 mutations have a 
tendency to decrease protein net charge and hence favor 
aggregation [15,16]; however, these trends have been 
questioned [6,15]. Key problems with identifying reliable 
trends have included limited patient data, as well as a lack of 
systematic, accurate analyses of sufficient numbers of mutant 
SOD1s. 
Wang et al. collected from the literature the most extensive 
sets of patient data and biophysical measurements to date. 
They applied a recalibrated Chiti-Dobson equation to 
ALS mutant SOD1 and found that increased aggregation 
propensity is significantly correlated with decreased patient 
survival. They also further validated that decreased mutant 
SOD1 stability tends to be associated with decreased 
survival. By then combining the effects of mutations on both 
aggregation propensity and stability, they found that the 
correlation with survival increases considerably, accounting 
for 69% of the variability in the ALS patient survival data. 
The improved correlation supports an intuitive and attractive 
physical model in which ALS is promoted by a decrease in 
SOD1 stability, which favors partial or complete unfolding, 
and this in turn favors formation of toxic aggregates (Figure 
1); this type of model is likely to be applicable to many other 
misfolding disease scenarios. 
Challenges and Approaches to Unraveling Protein 
Aggregation
A key question now is: why does the Wang et al. analysis 
not account for 100% of the SOD1 mutant patient data? 
There are many possible contributing factors. Foremost 
among these are serious limitations in the amount and 
quality of available patient data. Another important 
factor is limitations in protein stability data. Wang et al. 
have used a reasonable, but unorthodox, normalization 
approach to rank relative stabilities of mutant proteins by 
combining measurements of stability and apparent melting 
temperatures for apo SOD1, acquired under different 
conditions and with different methodologies. This can 
doi:10.1371/journal.pbio.0060193.g001 
Figure 1. Misfolding and Aggregation of SOD1
Wang et al.’s correlation of mutant SOD1 properties with disease 
duration [6] implicates two steps in the formation of aggregates of 
SOD1 in ALS: (1) native homodimeric metalloprotein, shown in ribbon 
representation (left) partially or completely unfolds to form a range 
of possible dimeric or monomeric aggregation-prone species, shown 
as a general grey irregular shape (middle), followed by (2) progressive 
assembly of the aggregation-prone species to form initially small soluble 
and later fibrillar aggregates (right panels). The structure of native SOD1 
was generated using MolMol [29] and Protein Data Bank accession 
code 1n18. Sites of ALS-associated mutations studied by Wang et al. 
are shown in red; bound copper and zinc ions are shown as blue and 
black spheres, respectively. The right panels are transmission electron 
microscopy images of apo SOD1 aggregates formed in vitro that 
strongly resemble granular and granule-coated fibrillar SOD1 aggregates 
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contribute to variability in a number of ways, which are likely 
offset to some extent by the averaging procedure employed 
by the authors. A key point for future studies, however, is 
to bear in mind possible systematic lowering of apparent 
melting temperatures if thermal unfolding is accompanied 
by aggregation, as could frequently occur [17,18]. This will 
likely affect apo and especially metallated SOD1 stabilities 
to varying extents for different states of different mutants. 
Also, the use of apo SOD1 stability, which is relatively lower 
and so can favor aggregation compared to metallated 
protein [19,20], may not report on all relevant aggregation 
processes. There is also evidence for aggregation of full- or 
part-metallated states of SOD1 [21,22], as well as aggregation 
of SOD1s altered by covalent modification such as oxidation 
or proteolysis [23,24]. Considering all these data, it appears 
that SOD1 may be poised to aggregate, likely in part due 
to its high concentration in neural cells, via a range of 
pathways. 
There are still more complexities that may weaken the 
correlation for the SOD1 patient data analysis. Wang et al. 
find that increased SOD1 net charge is weakly correlated 
with decreased survival time, opposite to the trends reported 
by Chiti and Dobson [13] and by other studies of SOD1 
mutations [15,16]. This requires further investigation, and 
may give clues to the perhaps oppositely charged targets 
of SOD1 and other protein aggregates. Finally, although 
different SOD1 mutations tend to be associated with different 
average disease durations, the actual durations for individuals 
with a given mutation are highly variable [6,25,26,27]. 
Such variability is not a special case, but is observed for 
many diseases. For ALS and other neurodegenerative 
diseases, it is increasingly apparent that variability occurs 
because additional effects, including age-dependent, 
environmental, and other genetic factors, modulate disease 
[27,28]. Further analysis of these factors will be critical for 
reaching a deep understanding of these complex diseases; an 
essential component will be the collection and reporting of 
comprehensive patient data by physicians. 
Clearly much remains to be learned about protein 
misfolding and aggregation in disease. The Wang et al. study 
has moved the field forward by formulating a quantitative 
analysis that better accounts for patient data by incorporating 
multiple factors to describe the complex effects of SOD1 
mutations. This provides a useful framework for developing 
further improved predictive equations by including additional 
effects of disease modulators, testing disease predictions, and 
pursuing common and distinct targets of protein aggregates in 
order to develop urgently needed therapeutic approaches. ◼
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